WebFunding. Intrommune Therapeutics has raised a total of $6.2M in funding over 5 rounds. Their latest funding was raised on Feb 8, 2024 from a Series B round. Intrommune … WebIntrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a new therapeutic approach for the treatment of peanut and other food allergies.Conducting allergy immunotherapy via teeth brushing is referred to as oral …
Intrommune Therapeutics (@intrommune) • Instagram photos and …
WebJul 16, 2024 · About Intrommune Therapeutics Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommunes core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a new … WebIntrommune Therapeutics is a biotechnology company developing patient-friendly therapies for the treatment of food allergies. The company’s oral mucosal … trinity grammar school term dates 2022
About Us Intrommune Therapeutics
WebIntrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and … WebSep 28, 2024 · About Intrommune Therapeutics Intrommune, dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy ... WebMar 12, 2024 · About Intrommune Therapeutics Intrommune, dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, ... trinity grammar term dates 2021